ATE522507T1 - Montelukast in fester phase - Google Patents
Montelukast in fester phaseInfo
- Publication number
- ATE522507T1 ATE522507T1 AT04765940T AT04765940T ATE522507T1 AT E522507 T1 ATE522507 T1 AT E522507T1 AT 04765940 T AT04765940 T AT 04765940T AT 04765940 T AT04765940 T AT 04765940T AT E522507 T1 ATE522507 T1 AT E522507T1
- Authority
- AT
- Austria
- Prior art keywords
- montelukast
- compound
- fixed phase
- formula
- formulated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50995703P | 2003-10-10 | 2003-10-10 | |
PCT/EP2004/011430 WO2005040123A1 (en) | 2003-10-10 | 2004-10-08 | Solid-state montelukast |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE522507T1 true ATE522507T1 (de) | 2011-09-15 |
Family
ID=34520017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04765940T ATE522507T1 (de) | 2003-10-10 | 2004-10-08 | Montelukast in fester phase |
Country Status (12)
Country | Link |
---|---|
US (1) | US7553853B2 (de) |
EP (1) | EP1678139B1 (de) |
JP (2) | JP2007508271A (de) |
AT (1) | ATE522507T1 (de) |
AU (1) | AU2004283832B2 (de) |
CA (1) | CA2541994A1 (de) |
ES (1) | ES2371549T3 (de) |
IL (1) | IL174758A (de) |
NO (1) | NO20062098L (de) |
PT (1) | PT1678139E (de) |
WO (1) | WO2005040123A1 (de) |
ZA (1) | ZA200602837B (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107612A1 (en) * | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
EP1678139B1 (de) | 2003-10-10 | 2011-08-31 | Synhton B.V. | Montelukast in fester phase |
EP1709001A2 (de) * | 2004-01-28 | 2006-10-11 | Pliva Istrazivanje i Razvoj d.o.o. | Feste formen von montelukastsäure |
US20050187243A1 (en) * | 2004-01-30 | 2005-08-25 | Valerie Niddam-Hildesheim | Montelukast free acid polymorphs |
EP1760077A1 (de) * | 2004-01-30 | 2007-03-07 | Teva Pharmaceutical Industries Ltd. | Polymorphe Formen vonMontelukast freie Säure |
WO2005075427A2 (en) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Montelukast sodium polymorphs |
BRPI0506610A (pt) | 2004-02-03 | 2007-05-02 | Chemagis Ltd | montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico |
MXPA06012220A (es) * | 2004-04-21 | 2007-07-18 | Teva Pharma | Procesos para preparar sodio de montelukast. |
US7501517B2 (en) * | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
US7829716B2 (en) * | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
US20090143590A1 (en) * | 2004-07-19 | 2009-06-04 | Matrix Laboratories Ltd. | Process for the Preparation of Montelukast and its Salts |
US9149472B2 (en) * | 2004-08-31 | 2015-10-06 | Jack William Schultz | Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders |
US20080214822A1 (en) * | 2004-11-30 | 2008-09-04 | Medichem, S.A. | Process For the Preparation of a Leukotriene Antagonist |
WO2006064269A2 (en) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Salts of leukotriene antagonist montelukast |
US7812168B2 (en) * | 2005-07-05 | 2010-10-12 | Teva Pharmaceutical Industries Ltd. | Purification of montelukast |
AR057908A1 (es) * | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar montelukast e intermediarios del mismo |
EP1968943B1 (de) * | 2005-12-13 | 2013-01-23 | MSN Laboratories Limited | Verbessertes verfahren zur herstellung von montelukast und dessen pharmazeutisch unbedenklichen salze |
EP1803457A1 (de) * | 2005-12-30 | 2007-07-04 | Krka Tovarna Zdravil, D.D., Novo Mesto | Pharmazeutische Zubereitung, welche Montelukast enthält |
EP1976522B2 (de) * | 2005-12-30 | 2019-07-03 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische zusammensetzung mit montelukast |
WO2007092031A1 (en) * | 2006-02-09 | 2007-08-16 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of montelukast sodium |
EP1996552A1 (de) * | 2006-03-17 | 2008-12-03 | Synthon B.V. | Montelukast-amantadin-salz |
EP1886998A1 (de) * | 2006-08-09 | 2008-02-13 | Esteve Quimica, S.A. | Verfahren zur Reinigung von Montelukast und dessen Aminesalzen |
SI22382A (sl) * | 2006-10-26 | 2008-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek za pripravo montelukasta |
WO2008062478A2 (en) * | 2006-11-20 | 2008-05-29 | Manne Satyanarayana Reddy | Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts |
US20080188664A1 (en) * | 2007-01-15 | 2008-08-07 | Chemagis Ltd. | Process for preparing montelukast sodium containing controlled levels of impurities |
CN101909626A (zh) * | 2007-10-25 | 2010-12-08 | 默克弗罗斯特加拿大有限公司 | 联合疗法 |
WO2009098271A1 (en) * | 2008-02-06 | 2009-08-13 | Farmaprojects, S.A. | Process for the purification of montelukast by the preparation of acid addition salts and tert-amylamine salt |
EP2276739A1 (de) * | 2008-04-25 | 2011-01-26 | Synthon B.V. | Verfahren zur herstellung von montelukast-zwischenprodukten |
EP2287154A1 (de) | 2009-07-14 | 2011-02-23 | KRKA, D.D., Novo Mesto | Effiziente Synthese zur Herstellung von Montelukast |
US8658208B2 (en) | 2010-02-26 | 2014-02-25 | Toray Industries, Inc. | Coated solid preparation |
WO2011121091A1 (en) | 2010-03-31 | 2011-10-06 | Krka, D.D., Novo Mesto | Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein |
US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
JP6488003B2 (ja) | 2014-04-25 | 2019-03-20 | アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー | 安定なモンテルカスト溶液 |
CN112789037A (zh) | 2018-09-06 | 2021-05-11 | 创新药物筛选有限公司 | 用于治疗哮喘或帕金森病的方法和药物组合物 |
CN111307979A (zh) * | 2020-03-14 | 2020-06-19 | 鲁南制药集团股份有限公司 | 一种孟鲁司特钠及其制剂的有关物质检测方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480717B1 (de) | 1990-10-12 | 1998-04-15 | Merck Frosst Canada Inc. | Ungesättigte Hydroxyalkylchinolinsäuren als Leukotrien-Antagonisten |
EP0480716A1 (de) * | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Gesättigte Hydroxyalkylchinolinsäuren zur Verwendung als Leukotrien-Antagonisten |
US5856322A (en) * | 1990-10-12 | 1999-01-05 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
US5266568A (en) * | 1990-10-12 | 1993-11-30 | Merck Frosst Canada, Inc. | Hydroxyalkylquinoline ether acids as leukotriene antagonists |
US5270324A (en) * | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
TW448160B (en) | 1993-12-28 | 2001-08-01 | Merck & Co Inc | Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists |
GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5523477A (en) * | 1995-01-23 | 1996-06-04 | Merck & Co., Inc. | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid |
US5869673A (en) * | 1997-02-28 | 1999-02-09 | Merck & Co., Inc. | Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde |
US6224907B1 (en) * | 1998-03-06 | 2001-05-01 | Alza Corporation | Anti-asthma therapy |
EA005116B1 (ru) * | 2000-10-20 | 2004-10-28 | Эли Лилли Энд Компани | НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗО[b]ТИОФЕНА |
CN1420113A (zh) * | 2001-11-16 | 2003-05-28 | 北京上地新世纪生物医药研究所 | 孟鲁司特钠的制备方法及其制备中间体 |
CN1171873C (zh) * | 2001-12-26 | 2004-10-20 | 北京上地新世纪生物医药研究所 | 一种孟鲁司特钠的制备方法及其制备中间体 |
AU2003209043A1 (en) | 2002-02-07 | 2003-09-02 | Dr. Reddy's Laboratories Ltd. | Novel anhydrous amorphous forms of montelukast sodium salt |
US20050107612A1 (en) * | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
US8450491B2 (en) | 2003-06-06 | 2013-05-28 | Morepen Laboratories Limited | Method for the preparation of montelukast acid and sodium salt thereof in amorphous form |
EP1678139B1 (de) | 2003-10-10 | 2011-08-31 | Synhton B.V. | Montelukast in fester phase |
US20050187243A1 (en) * | 2004-01-30 | 2005-08-25 | Valerie Niddam-Hildesheim | Montelukast free acid polymorphs |
US7189853B2 (en) * | 2004-04-15 | 2007-03-13 | Dr. Reddy's Laboratories Limited | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts |
US7829716B2 (en) * | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
US7501517B2 (en) * | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
-
2004
- 2004-10-08 EP EP04765940A patent/EP1678139B1/de not_active Not-in-force
- 2004-10-08 AT AT04765940T patent/ATE522507T1/de not_active IP Right Cessation
- 2004-10-08 IL IL174758A patent/IL174758A/en not_active IP Right Cessation
- 2004-10-08 PT PT04765940T patent/PT1678139E/pt unknown
- 2004-10-08 JP JP2006530147A patent/JP2007508271A/ja not_active Withdrawn
- 2004-10-08 CA CA002541994A patent/CA2541994A1/en not_active Abandoned
- 2004-10-08 US US10/960,639 patent/US7553853B2/en not_active Expired - Fee Related
- 2004-10-08 AU AU2004283832A patent/AU2004283832B2/en not_active Ceased
- 2004-10-08 WO PCT/EP2004/011430 patent/WO2005040123A1/en active Application Filing
- 2004-10-08 ES ES04765940T patent/ES2371549T3/es active Active
-
2006
- 2006-04-06 ZA ZA200602837A patent/ZA200602837B/xx unknown
- 2006-05-10 NO NO20062098A patent/NO20062098L/no not_active Application Discontinuation
-
2011
- 2011-10-24 JP JP2011233150A patent/JP2012072149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO20062098L (no) | 2006-05-10 |
EP1678139A1 (de) | 2006-07-12 |
US7553853B2 (en) | 2009-06-30 |
AU2004283832A1 (en) | 2005-05-06 |
US20050107426A1 (en) | 2005-05-19 |
WO2005040123A1 (en) | 2005-05-06 |
ES2371549T3 (es) | 2012-01-05 |
IL174758A (en) | 2012-09-24 |
CA2541994A1 (en) | 2005-05-06 |
PT1678139E (pt) | 2011-11-28 |
JP2007508271A (ja) | 2007-04-05 |
JP2012072149A (ja) | 2012-04-12 |
IL174758A0 (en) | 2006-08-20 |
AU2004283832B2 (en) | 2011-04-07 |
ZA200602837B (en) | 2007-09-26 |
EP1678139B1 (de) | 2011-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE522507T1 (de) | Montelukast in fester phase | |
TW200616976A (en) | Pyrimidine derivatives | |
LUC00155I1 (de) | ||
TW200738241A (en) | Pyridazine derivatives | |
TW200626558A (en) | Indazolone derivatives | |
WO2006010546A3 (en) | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors | |
ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
MX2010005824A (es) | Derivados de aminotiazol. | |
TW200740764A (en) | Pyrazolone derivatives | |
EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
BR0317749A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
TW200616958A (en) | New alkyl-pyridines as 11-beta inhibitors for diabetes | |
ATE297910T1 (de) | Retinoid x rezeptormodulatoren | |
ME01395B (de) | Verfahren zur Herstellung von (1S)-4,5-Dimethoxy-1-(methylaminomethyl)-benzocyclobutan und deren Säureadditionssalze, sowie ihre Verwendung für die Synthese von Ivabradin und deren Säureadditionssalze von pharmazeutischen verträglichen Säure | |
EP1340755A4 (de) | Mittel mit wirkung gegen helicobacter | |
MXPA06000921A (es) | Derivados de benzamidazoles como inhibidores de mek. | |
DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
WO2005120516A3 (en) | Hiv integrase inhibitors | |
NO20085317L (no) | Imidazoazepinonforbindelser | |
IS7482A (is) | Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf | |
MX2009003169A (es) | Derivados de sulfonamida. | |
HRP20060023A2 (en) | Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions | |
MY135646A (en) | Indolyl derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |